After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Medtronic USA Inc.'s argument that its implantable heart monitors are “medicines” exempt from sales tax seemed to divide two justices on a California appeals court panel at oral arguments Monday.

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.

Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...